Literature DB >> 10929089

Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat.

S M Parsadaniantz1, A Lebeau, P Duval, B Grimaldi, B Terlain, B Kerdelhué.   

Abstract

The limited entry of interleukin-1beta (IL-1beta) into the central nervous system has led to the hypothesis that IL-1beta acts, through IL-1beta receptors located notably on endothelial cells, on the release of prostaglandins which in turn stimulate the hypothalamic-pituitary-adrenal (HPA) axis. We used cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors, before the injection of IL-1beta, to explore the role of arachidonic acid metabolic pathways on HPA axis activation. Adult male rats were i.m injected 20 min before i.p injection of IL-1beta, with (i): a COX-1/COX-2 inhibitor (ketoprofen); (ii) a COX-2 selective inhibitor (NS 398); or (iii) a 5-LOX inhibitor (BW A4C). Following this, rats were killed 90 min after i.p. IL-1beta injection and analysis for plasma adrenocorticotropic hormone (ACTH) and corticosterone concentrations and determination of anterior pituitary pro-opio melanocortin (POMC) gene transcription was conducted. Administration of the COX-1/COX-2 inhibitor led to a complete blockage of ACTH and corticosterone secretion and POMC gene transcription. The COX-2 inhibitor led to a complete blockade of ACTH secretion and POMC gene transcription but had no effect on corticosterone secretion. The 5-LOX inhibitor had no significant effect on any parameter. These results demonstrate the crucial role of eicosanoid pathways in mediating the stimulation of the HPA axis induced by IL-1beta. Moreover, we found a clear dissociation of the effect of the blockage of COXs upon ACTH and corticosterone secretion, suggesting that IL-1beta may act at the brain as well as at the adrenal cortex to stimulate the secretion of corticosterone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929089     DOI: 10.1046/j.1365-2826.2000.00517.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  7 in total

1.  Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat.

Authors:  Ninitha Asirvatham-Jeyaraj; Andrew J King; Carrie A Northcott; Shivanshu Madan; Gregory D Fink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-06       Impact factor: 4.733

2.  Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats.

Authors:  Richard De La Garza; Gregory M Asnis; Kevin R Fabrizio; Erika Pedrosa
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

3.  Reconsidering Dietary Polyunsaturated Fatty Acids in Bipolar Disorder: A Translational Picture.

Authors:  Erika F H Saunders; Christopher E Ramsden; Mostafa S Sherazy; Alan J Gelenberg; John M Davis; Stanley I Rapoport
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

Review 4.  Neural circuitry engaged by prostaglandins during the sickness syndrome.

Authors:  Clifford B Saper; Andrej A Romanovsky; Thomas E Scammell
Journal:  Nat Neurosci       Date:  2012-07-26       Impact factor: 24.884

5.  Effect of naproxen on the hypothalamic-pituitary-adrenal axis in healthy volunteers.

Authors:  Agnes M M Eijsbouts; Marlies J E Kempers; Renske S A Kramer; Maria T E Hopman; Frank H J van den Hoogen; Ronald F J M Laan; Ad R M M Hermus; Fred C G J Sweep; Leo B A van de Putte
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 6.  Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2009-01       Impact factor: 6.186

Review 7.  Inflammatory response following diffuse axonal injury.

Authors:  Yu Lin; Liang Wen
Journal:  Int J Med Sci       Date:  2013-03-13       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.